论文部分内容阅读
[目的]观察比较卡培他滨与比替吉奥对晚期胃癌的临床疗效及其毒副反应情况。[方法]选取52例晚期胃癌患者,随机分为卡培他滨组和替吉奥组,比较2组患者治疗后效果及毒副反应发生情况。[结果]卡培他滨组治疗有效率为38.5%、疾病控制率为65.4%,替吉奥组治疗有效率34.6%、疾病控制率为57.7%,2组患者治疗有效率、疾病控制率比较差异均无统计学意义(P>0.05);卡培他滨组骨髓抑制、胃肠道反应、手足综合征、口腔炎等毒副反应发生率与替吉奥组比较差异均无统计学意义(P>0.05)。[结论]卡倍他滨或替吉奥治疗晚期胃癌疗效相当,毒副反应无明显差异,均可用于晚期胃癌的化疗用药。
[Objective] To observe the clinical efficacy and adverse reactions of capecitabine and bidetizole in advanced gastric cancer. [Methods] Fifty-two patients with advanced gastric cancer were selected and randomly divided into capecitabine group and treatment group. The effects and side effects of the two groups after treatment were compared. [Results] The effective rate of capecitabine group was 38.5%, the rate of disease control was 65.4%, the effective rate of treatment was 34.6% and the rate of disease control was 57.7%. The treatment efficiency and disease control rate of two groups were compared (P> 0.05). The incidence of bone marrow suppression, gastrointestinal reaction, hand-foot syndrome, stomatitis and other toxic reactions in capecitabine group was not significantly different from that of the control group (P> 0.05) P> 0.05). [Conclusion] The curative effect of capecitabine or treatment of advanced gastric cancer for the same, no significant differences in side effects, can be used for chemotherapy of advanced gastric cancer.